In vitro Apramycin Activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa
Autor: | Christopher McCoy, Anders H. Berg, Anthony D. Kang, George M. Eliopoulos, James E. Kirby, Kenneth P. Smith |
---|---|
Rok vydání: | 2017 |
Předmět: |
Acinetobacter baumannii
0301 basic medicine Microbiology (medical) 030106 microbiology Microbial Sensitivity Tests Pharmacology medicine.disease_cause Apramycin Microbiology 03 medical and health sciences Drug Resistance Multiple Bacterial polycyclic compounds medicine Tobramycin Animals Humans Nebramycin Amikacin biology Pseudomonas aeruginosa Aminoglycoside General Medicine biochemical phenomena metabolism and nutrition Acinetobacter bacterial infections and mycoses biology.organism_classification Anti-Bacterial Agents 030104 developmental biology Infectious Diseases bacteria Gentamicin Gentamicins medicine.drug |
Zdroj: | Diagnostic Microbiology and Infectious Disease. 88:188-191 |
ISSN: | 0732-8893 |
Popis: | The in vitro activity of apramycin was compared to that of amikacin, gentamicin, and tobramycin against multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Apramycin demonstrated an MIC50/MIC90 of 8/32μg/ml for A. baumannii and 16/32μg/ml for P. aeruginosa. Only 2% of A. baumannii and P. aeruginosa had an MIC greater than an epidemiological cutoff value of 64μg/ml. In contrast, the MIC50/MIC90 for amikacin, gentamicin, and tobramycin were ≥64/>256μg/ml for A. baumannii with 57%, 95%, and 74% of isolates demonstrating resistance, respectively, and the MIC50/MIC90 were ≥8/256μg/ml for P. aeruginosa with 27%, 50%, and 57% of strains demonstrating resistance, respectively. Apramycin appears to offer promising in vitro activity against highly resistant pathogens. It therefore may warrant further pre-clinical study to assess potential for repurposing as a human therapeutic and relevance as a scaffold for further medicinal chemistry exploration. |
Databáze: | OpenAIRE |
Externí odkaz: |